Key result
A biomarker panel of four maternal serum miRNAs (miR-142-5p, miR-1275, miR-4666a-3p, and miR-3664-3p) distinguished fetal congenital heart defects from healthy controls (AUC 0.920; p < 0.0001).
Why the study?
Can maternal circulating microRNAs serve as non-invasive biomarkers for the prenatal diagnosis of fetal congenital heart defects?
Case-Control (n=110)
Can maternal circulating microRNAs serve as non-invasive biomarkers for the prenatal diagnosis of fetal congenital heart defects?
Effect estimate: AUC 0.920
p-value: p=< 0.0001
A panel of four maternal circulating miRNAs shows high diagnostic accuracy for the non-invasive prenatal detection of fetal congenital heart defects.
May support maternal miRNA panels for non-invasive fetal CHD detection; hypothesis-generating and should not yet change practice.
OBJECTIVE: The discovery of cell free fetal microRNAs (miRNAs) in maternal circulation has opened up novel probabilities for non-invasive prenatal diagnosis. This study aims to investigate circulating miRNAs as potential biomarkers in the serum of pregnant women with congenital heart defect (CHD) fetuses. METHOD: A total of 110 pregnant women including 50 CHD cases and 60 healthy controls were included in this study. miRNA microarray followed by real-time PCR was used to explore miRNA expression. Receiver operating characteristic (ROC) curves were calculated to assess the diagnostic capability of miRNAs for fetal CHDs. RESULTS: 38 Serum miRNAs were revealed to be differentially expressed in the CHD group as compared to control group via microarray. Among these, nine down-regulated and three up-regulated miRNAs were validated by real-time PCR. Ten of these miRNAs were rapidly reduced in the normal maternal serum after delivery as compared to before delivery. In particular, we identified a biomarker panel consisting of four miRNAs (miR-142-5p, miR-1275, miR-4666a-3p and miR-3664-3p) capable of distinguishing CHDs from controls (area under the ROC curve (AUC), 0.920; p < 0.0001). CONCLUSION: The discovery of these dysregulated pregnancy-associated miRNAs in maternal serum may be potential biomarkers for non-invasive prenatal diagnosis of fetal CHDs.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2018) conducted a case-control in fetal congenital heart defects (n=110). Maternal circulating microRNAs vs. Healthy controls was evaluated on Distinguishing CHDs from controls (AUC 0.920, p=< 0.0001). A biomarker panel of four maternal serum miRNAs (miR-142-5p, miR-1275, miR-4666a-3p, and miR-3664-3p) distinguished fetal congenital heart defects from healthy controls (AUC 0.920; p < 0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: